Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
Blood pressure lowering efficacy of alpha blockers for primary hypertension
Cochrane Reviews, 10/09/09
Heran BS et al. – The authors found only 10 trials studying the blood pressure lowering ability of 4 different alpha blockers in 1175 participants. Based on the limited number of published RCTs, the BP lowering effect of alpha blockers is modest; the estimate of the magnitude of trough BP lowering of –8/–5 mmHg is likely an overestimate. There are no clinically meaningful BP lowering differences between different alpha blockers. The review did not provide a good estimate of the incidence of harms associated with alpha blockers because of the short duration of the trials and the lack of reporting of adverse effects in many of the trials.
Related Articles
Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery
Cochrane Reviews, 10/20/09
Relevance Score: 67%
Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis
Cardiovascular Research, 11/19/09
Relevance Score: 66%
Modulations of autonomic cardiovascular control following acute alpha-adrenergic treatment in chronic hypotension
Hypertension Research, 11/09/09
Relevance Score: 64%
Pharmacodynamic Interactions with Exercise and Beta-Blocker Medications
American Journal of Lifestyle Medicine, 11/16/09
Relevance Score: 62%
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men
Cochrane Reviews, 10/19/09
Relevance Score: 62%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Inotrope and vasopressor use in the emergency department
Emergency Medicine Australasia, 12/10/09
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy
Current Medical Research and Opinion, 12/10/09
Fyi from human genome sciences: gsk initiates second pivotal phase 3 trial for investigational cardiovascular medication darapladib
Human Genome Sciences, 12/10/09
Sponsor
Article Search
Sponsor


See Latest Articles


